{"id":106578,"date":"2026-07-22T12:16:43","date_gmt":"2026-07-22T12:16:43","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/106578\/"},"modified":"2026-07-22T12:16:43","modified_gmt":"2026-07-22T12:16:43","slug":"novartis-stock-bounds-for-buy-point-why-shares-are-on-the-rise","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/106578\/","title":{"rendered":"Novartis Stock Bounds For Buy Point; Why Shares Are On The Rise"},"content":{"rendered":"<p>Novartis (NVS) stock popped Tuesday on a solid second-quarter report, despite feeling continued heat from generic rivals for big-name drugs like Entresto and Xolair. In total, sales grew 3% to $14.41 billion, easily topping expectations for $14.07 billion, according to FactSet. Excluding the impact of exchange rates, sales ticked 1% higher. But, while volume contributed 18 percentage points to that\u2026<\/p>\n<p>Copyright \u00a92026 Investor&#8217;s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis (NVS) stock popped Tuesday on a solid second-quarter report, despite feeling continued heat from generic rivals for&hellip;\n","protected":false},"author":2,"featured_media":106579,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[23557,23558,230,206,29189],"class_list":["post-106578","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-all-news-and-stock-ideas","tag-biotech-and-pharma-stock-news","tag-earnings","tag-novartis","tag-tech-earnings"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116963585906119220","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/106578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=106578"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/106578\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/106579"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=106578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=106578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=106578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}